OPINION Progress in the diagnosis and management of pulmonary hypertension in children Jeremy Nicolarsen and Dunbar Ivy Purpose of review Pulmonary hypertension is a complex disease that extends beyond merely elevated pulmonary blood pressures and right ventricular dysfunction. Its multiple causes and ever-expanding diagnostic tools and therapeutic approaches make it a heterogeneous disease with widely variable clinical sequelae. There are still many unanswered questions that challenge our understanding of this disease.
INTRODUCTION
Pulmonary hypertension (PH) continues to be a significant contributor to morbidity and mortality in pediatric patients. Its broad spectrum of pathogenesis, disease manifestation, therapeutic approach, and prognosis makes it a challenging, yet rewarding, area of medicine. From fetus to adolescent, child to adult, pulmonary hypertension can involve or result from genetic, cellular, and physiologic derangements of the pulmonary, cardiovascular, hepatic, hematologic, and connective tissue systems. In children, prematurity, congenital heart disease (CHD), and other diseases such as bronchopulmonary dysplasia (BPD), play a particularly important role in lung development and integrity. Regardless of the cause, pulmonary hypertension and pulmonary arterial hypertension (PAH), which more specifically defines abnormalities of the precapillary pulmonary vasculature, share at their core the untoward effects of elevated pulmonary pressures on right ventricular size, function, and overall health and mortality. This review will discuss recent advances in our understanding and management of pediatric pulmonary hypertension.
UPDATES ON THE CLINICAL CLASSIFICATION OF PULMONARY HYPERTENSION
To systematically and appropriately apply what we learn in pulmonary hypertension, a diagnostic classification has been developed and modified at the World Symposiums on Pulmonary Hypertension (WSPH). Initially developed at the second WSPH in Evian (France) in 1998 and subsequently updated in 2003 at the third WSPH in Venice (Italy) [1] , this clinical classification system identifies five categories of disorders that cause pulmonary hypertension, with each group sharing similar hemodynamic, pathologic, and management features: PAH (group 1), pulmonary hypertension due to left heart disease (group 2), pulmonary hypertension due to chronic lung disease and/or hypoxia (group 3), chronic thromboembolic pulmonary hypertension (group 4), and pulmonary hypertension due to multifactorial mechanisms (group 5).
The last significant changes to this classification system came at the fourth WSPH in Dana Point (USA) in 2008 [2] and have since been widely accepted in clinical and regulatory realms. It was not until the most recent fifth symposium in Nice (France) in 2013, however, that additional pediatricspecific categories of pulmonary hypertension were added and previous ones expanded, resulting in a new classification system that for the first time encompasses pulmonary hypertension patients of all ages [3 && ]. A separate pediatric classification system was discussed in Nice, but the fifth WSPH Task Force on pediatric pulmonary hypertension ultimately decided that children and adolescents should retain the same pulmonary hypertension classification when they transition from pediatric to adult care. The 2013 updated classifications of 
KEY POINTS
The WHO classification of pulmonary hypertension was amended in 2013 and now includes improved identification of pediatric-specific characteristics of the disease.
The presence of pulmonary hypertension increases morbidity and mortality in patients with BPD and relates to impaired vascular growth and signaling, coupled with hypertensive vasculopathy and remodeling stimulated by chronic hypoxemia.
While echocardiography and cardiac catheterization remain key diagnostic tools in pulmonary hypertension, novel uses of MRI and new targets in the areas of exercise physiology, biomarkers, and genetics are enhancing our diagnostic and prognostic abilities.
Although 80% of familial PAH is caused by mutations of the BMPR2, almost all forms of pulmonary hypertension share abnormal BMPR2 signaling.
Within the past year, three new drugs were approved by the FDA to treat PAH in adults and will encourage ongoing discussion about use in children. Additionally, the chronic use of sildenafil in pediatric patients came under scrutiny but continues to be a mainstay of therapy at lower doses.
(c) Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders (d) Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis, segmental PH. The expanded classification system now includes independent categories of persistent pulmonary hypertension of the newborn, which is a separate category due to its unique pathobiology and greater likelihood to resolve, congenital or acquired left heart inflow or outflow tract obstruction, such as supravalvar mitral ring, cor triatriatum, and left ventricular outflow obstruction, and congenital cardiomyopathies (a new subtype of group 2). These, coupled with previous categories of PAH due to CHD, pulmonary hypertension due to developmental lung diseases, and pulmonary hypertension due to chronic hemolytic anemia such as sickle cell disease (SCD), better represent the spectrum of pulmonary hypertension in children and adolescents. Of note, SCD and other chronic hemolytic anemias were moved to group 5, given their disparate pathology, hemodynamics (including possibility of left ventricular diastolic dysfunction), and response to therapy. Finally, segmental pulmonary hypertension, which incorporates patients with pulmonary atresia with ventricular septal defect, was added as a subtype of group 5 disease. The fifth WSPH went on to emphasize the lifelong nature of PAH associated with CHD and also expanded its section on heritable PAH as new culprit gene mutations have been discovered in SMAD9 [4] , caveolin-1 [5] , and potassium channel KCNK3 [6 & ].
PATHOPHYSIOLOGY
The pathophysiology of pulmonary vascular disease resulting in pulmonary hypertension has routinely centered on pulmonary arteriopathy characterized by endothelial smooth muscle dysfunction, intimal thickening, and medial hypertrophy, with increased production of proliferative factors and decreased function of vasodilatory mediators [7, 8] . Children and adolescents often have idiopathic PAH (IPAH) or CHD-PAH [9] [10] [11] [12] and in these cases this pathophysiology applies. Of additional importance in the pediatric population, however, is altered lung development and integrity, as is manifested in BPD, the most common chronic lung disease in children. This disease carries significant morbidity and mortality, especially when pulmonary pressures are elevated, and its impact on Pediatric pulmonary hypertension is substantial and worth further discussion. The incidence of BPD has widely varied within the literature, but may be as high as 18% in infants weighing less than 1500 g [13 & ]. In infants with BPD, pulmonary hypertension can occur in approximately 18-25% [13 & ,14,15 & ]. In a recent, large, prospective, single-center study, 145 extremely low-birth-weight infants (birth weight less than 1000 g) underwent screening echocardiography at a median age of 31 days of life and 6% (9/145) were found to have pulmonary hypertension, with an additional 12% (17/145) developing signs of pulmonary hypertension on subsequent echocardiograms, with a median age of diagnosis of 112 days of life [15 & ]. These studies have consistently shown that infants with more severe BPD are at greater risk of developing pulmonary hypertension and have longer hospitalization times and higher mortality ( Fig. 1 ) [16 && ]. The mortality can be significant, with another retrospective study of patients with BPD and pulmonary hypertension showing mortality rates as high as 36% at 6 months, 39% at 1 year, and 48% at 2 years after the diagnosis of pulmonary hypertension [17] . Although this study predated pulmonary hypertension-specific management therapies in BPD care, it highlights the significance of this disease in already vulnerable, premature infants.
Exploring BPD's pathophysiology has informed our understanding of pulmonary vascular biology in pulmonary hypertension as was nicely described in a 2013 Current Opinion in Pediatrics review by Mourani and Abman [16 && ]. Briefly, impaired vascular growth and signaling, coupled with hypertensive vasculopathy and remodeling that occurs in the setting of lung and heart disease and chronic hypoxemia, provides the perfect substrate for the development of pulmonary hypertension [16 && ]. The same group expanded its discussion of pulmonary hypertension pathogenesis and management in an extensive review just recently published [18 && ]. Noninvasive diagnosis and surveillance of pulmonary hypertension now goes beyond the echocardiography laboratory and into the MRI suite, in which reliable anatomical and functional assessments of the right ventricle and pulmonary arteries can be performed. Although a challenging test in young patients with severe pulmonary hypertension who are at high risk of problems with sedation, cardiac magnetic resonance (CMR) is increasingly becoming faster and more readily available. A recent study of 100 pediatric patients evaluated the prognostic capability of CMR in the assessment of pulmonary hypertension and found that measurements of right ventricular ejection fraction and left ventricular stroke volume index were most strongly predictive of survival [27 && ]. Others have looked at wall shear stress in pulmonary arteries by phase contrast imaging in CMR and identified that it is decreased in patients with PAH relative to controls because of greater pulmonary artery dilatation with preserved systolic flow. This abnormal shear stress is believed to affect cellular mechanics, with altered inflammatory cytokine expression in more distal vessels, resulting in the medial hypertrophy and vascular pathology seen in pulmonary hypertension [28 & ].
DIAGNOSIS
In those patients with suspected pulmonary hypertension by echocardiography or CMR, right heart catheterization remains the definitive test to confirm pulmonary hypertension (mean pulmonary artery pressure, mPAp > 25 mmHg), identify PAH (pulmonary hypertension plus a pulmonary capillary wedge pressure < 15 mmHg and pulmonary vascular resistance, PVR > 3 Wood units), and perform acute vasoreactivity testing (AVT) with nitric oxide to guide management. AVT is routinely performed in patients with IPAH or heritable PAH, and translating this practice to those with PAH due to CHD is often done as well. In children, calcium channel blockade (CCB) can be used as initial therapy in those who have a 'positive response' to AVT with nitric oxide, as defined by a decrease in mPAp of at least 20% with a cardiac index that increases or remains unchanged and a ratio of pulmonary to systemic vascular resistance that decreases or remains unchanged [29] . In adults, a decrease in mPAp and PVR greater than 20% [30] or a decrease in the mPAp by 10 mmHg to a value less than 40 mmHg with no decrease in cardiac output [31] defines a positive response to AVT. The timing of changing a patient's management from the pediatric to adult definition of a positive response to AVT is unknown but is likely in midadolescence. Additional hemodynamic parameters that are prognostic in pulmonary hypertension include the ratio of mPAp to mean systemic artery pressure, PVR to systemic vascular resistance, elevated right atrial pressure (primarily in adults), indexed PVR greater than 20 Wood units Â m 2 [32 && ,33,34] , and the persistence of positive vasoreactivity testing, the latter of which has been shown to correlate with improved survival [11] . Recently, right ventricular stroke work (RVSW), or the product of mPAp and stroke volume and an assessment integrating contractility, afterload, and ventriculo-arterial coupling, has been shown to correlate with disease severity [35 & ]. At the fifth WSPH, the Task Force on Diagnosis and Assessment nicely discussed the challenging questions surrounding hemodynamic definitions of pulmonary hypertension and PAH [19 && ]. The 6-min walk distance and cardiopulmonary exercise test (CPET) remain less invasive and relatively inexpensive ways to follow patients between cardiac catheterizations and CMRs. Although less validated in the pediatric population, these tests can be reliably performed and are most helpful as a surveillance tool for an individual patient. Within the CPET, evaluation of markers other than peak oxygen consumption, such as the ventilatory efficiency slope (VE/VCO2 slope), has also been shown to correlate with functional capacity, disease severity, and outcomes [36 & ]. These tests have correlated with the WHO functional class assessment, which has been shown to contribute to a risk equation for PAH worsening and survival [37] . Often, simply identifying the patient's functional class goes a long way to helping with prognosis and management. A pediatric-specific functional class has been proposed, but not yet validated [38] .
Finally, our diagnostic and surveillance capabilities are improving through the measurement of serum biomarkers such as brain natriuretic peptide (BNP) or the inactive N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) which, when elevated, have been associated with greater risk of death [39] [40] [41] [42] [43] . Of additional help is our growing ability to identify specific gene mutations such as those described previously. The genetic and epigenetic evaluation of patients with pulmonary hypertension will increasingly become a part of our diagnostic and therapeutic approach to this disease and often informs our understanding of pathophysiology, as has been told in the story of BMPR2. Mutations in this gene have been involved in multiple signaling pathways implicated in the development of pulmonary hypertension. Our current understanding of BMPR2 regulation suggests that although 80% of familial pulmonary hypertension is caused by a BMPR2 mutation, almost all forms of pulmonary hypertension share abnormal BMPR2 signaling [44 && ].
MANAGEMENT Inherent in studying any complex and rare pediatric disease is the lack of large clinical trials in children and the need to extrapolate data from adult studies or experiences. This is particularly the case in pulmonary hypertension management, given the breadth of disease phenotype and severity, coupled with an increasingly growing list of possible therapies, many with significant adverse effects. At the fifth WSPH in Nice, a pediatric-specific treatment algorithm was proposed using expert opinion, and although most applicable to children with IPAH, it is worth reviewing further (Fig. 2) . Basic therapies, such as diuretics, oxygen, anticoagulation, and digoxin, should be used on an individual basis and are often started during the diagnostic evaluation of a newly symptomatic patient. Right heart catheterization is routinely performed and should include AVT, with the initiation of CCB only in children with a positive AVT response, as described previously. For those with a negative response to AVT or failure to improve with CCB, risk stratification should guide initial therapeutic choices. Severe right ventricular enlargement or dysfunction, pericardial effusion, significantly elevated or rising BNP or NT-proBNP, progression of symptoms, clinical evidence of right ventricular failure, poor functional class (WHO class III, symptoms with most activities, or WHO class IV, symptoms at rest), and syncope all suggest higher risk (Table 1) , for which early combination therapy or IV therapy should be initiated [32 && ]. In those without these risk factors, single-agent oral therapy should be followed later by combination therapy if needed. Important in any of this management is frequent reassessment of these parameters and willingness to adjust therapies before right ventricular dysfunction or right heart failure ensues.
Initial single agent oral therapy should include either an endothelin receptor antagonist such as bosentan [45] , ambrisentan [46] , or macitentan [47 (FDA) . Perhaps more commonly started is a phosphodiesterase-5 inhibitor (PDE-5i) such as tadalafil [48] or sildenafil [49 && ]. Sildenafil came under particular scrutiny by the FDA during the summer of 2012 because of a (barely) clinically insignificant improvement in the prespecified primary outcome, peak oxygen consumption (P ¼ 0.056), in the total aggregate of low-dose (10 mg), medium-dose (10-40 mg), and high-dose (20-80 mg) administrations of sildenafil in the Sildenafil in Treatment-Naive Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension (STARTS-1) trial [49 && ], coupled with an increased risk of mortality in the high-dose group with chronic use, who not surprisingly happened to have worse baseline hemodynamics before drug administration [50 && ]. In August 2012, the FDA went on to place a drug warning on (chronic) sildenafil use in children (ages 1-17 years) [51] , inciting a collective gasp from parents of children on this medication and providers who had been prescribing it for years. Some providers interpreted this warning as a contraindication to administer the drug to children and stopped prescribing it altogether, so the FDA later went on to clarify their stance in March 2014, stating that 'this (initial) recommendation was not intended to suggest that Revatio should never be used in children' [52 && ]. On further evaluation of these studies and recent review of pediatric pulmonary hypertension registries, many pulmonary hypertension providers are in agreement that low-dose sildenafil has a role in the management of this disease and that high-dose sildenafil should be avoided [53 & -55 & ]. Importantly, PDE-5i therapy should not be abruptly stopped as pulmonary hypertension worsening and mortality may increase [54 & ].
In children who fail single-agent oral therapy or who have substantial risk factors for severe pulmonary hypertension, combination therapy (early or add-on) or initiation of inhaled, subcutaneous, or intravenous prostacyclins may improve survival ( Fig. 3) [56 && ]. Inhaled prostacyclins (iloprost and treprostinil) have been shown to be a benefit as addon therapy in low-risk patients [57, 58] or as a diagnostic tool in AVT [59] . High-risk patients warrant initiation of intravenous epoprostenol or treprostinil [59, 60] . Subcutaneous prostacyclin therapy is additionally carrying momentum [61] . Finally, those high-risk patients who are still declining despite prostanoids deserve consideration for atrial septostomy [62] or lung transplantation [63] . A descending aorta to left pulmonary artery shunt has been advocated by some groups [64] and may even be placed transcutaneously, but experience is limited [65] .
Newer therapeutic agents and novel approaches include the recently FDA-approved soluble guanylate cyclase stimulator, riociguat, which increases cyclic guanosine monophosphate production and vasodilation independent of the nitric oxide pathway [66] . This medication has been approved for adults with WHO group 1 PAH and patients with CTEPH who are not candidates for pulmonary endarterectomy or who have failed this therapy [67 & ]. Riociguat causes bone dysplasia and growth plate injury in young, growing rats, raising questions as to its use in pediatric patients [68] . Additionally, oral treprostinil was recently FDA-approved and is now commercially available [69 & ,70 & ]. As newer oral agents continue to emerge, the risks of chronic intravenous or subcutaneous prostanoid infusion may be avoided in some patients. Despite these advances, physicians remain challenged by the lack of evidence in deciding on drug therapy in children with pulmonary hypertension.
CONCLUSION
Much of what we know about pulmonary hypertension in children and adolescents, including our understanding of its pathogenesis and therapy, continues to be largely extrapolated from adult patients and studies. Although collaboration between centers and within multidisciplinary teams is certainly improving, much is still to be known about the unique aspects of pulmonary hypertension in pediatric patients. Advancing our diagnostic and therapeutic understanding of pulmonary hypertension comes through review of the recent literature, but additionally important is our development of patient registries as well as the ongoing participation of patients and providers in national and international organizations devoted to pulmonary hypertension research. It is through this collective approach to this disease that we will continue to improve care of these complex patients.
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